Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs NIO Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while NIO Inc. trades at $3.4 (market cap $8.76B). The key difference: Kymera Therapeutics Inc. Common Stock and NIO Inc. are close in size by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and NIO Inc. for 81 Days on average.
| KYMR | NIO | |
|---|---|---|
Market Cap | $8.88B | $8.76B |
Volume | 1,028,790 | 36,159,487 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $7.42 |
52-Week Low | $55.80 | $3.37 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $8.27B | $6.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NIO trades at $3.56, up 2.59% today but remains near 52-week lows amid a bearish technical outlook. The Chinese EV maker shows improving fundamentals with revenue growth to $87.49B in 2025 and narrowing losses, though profitability remains elusive. Recent strategic moves include a battery-swap partnership with Geely valued at $2.38B, potentially expanding NIO's network reach and utilization.
While analyst consensus leans bullish with a $6.23 price target, significant risks persist including intense price competition in China's EV market, negative cash flows, and high debt levels. The stock offers speculative upside if execution improves, but requires monitoring of quarterly earnings and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
